A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
11/2004
11/04/2004	CA2522730A1 Compositions and methods for sirna inhibition of angiopoietin 1 and 2 and their receptor tie2
11/04/2004	CA2522718A1 A novel method of modulating bone-related activity
11/04/2004	CA2522669A1 Postnatal stem cells and uses thereof
11/04/2004	CA2522637A1 Modified irna agents
11/04/2004	CA2522560A1 Antisense modulation of apolipoprotein c-iii expression
11/04/2004	CA2522359A1 Pathotropic retroviral vector used to deliver diagnostic or therapeutic compositions
11/04/2004	CA2522081A1 Recombinant influenza viruses holding a mutation in a transmembrane protein gene
11/03/2004	EP1473369A2 Compositions and methods for delivery of genetic material
11/03/2004	EP1473365A1 Angiogenesis inhibitors
11/03/2004	EP1473360A2 Methods for the ex-vivo replication and stable genetic transformation of human stem cells
11/03/2004	EP1473303A1 Novel proteins and dnas thereof
11/03/2004	EP1472544A2 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/03/2004	EP1472540A2 Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
11/03/2004	EP1472515A2 MINRs AS MODIFIERS FO INSULIN RECEPTOR SIGNALING AND METHODS OF USE
11/03/2004	EP1472379A1 Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications
11/03/2004	EP1472376A2 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
11/03/2004	EP1472375A1 Gene products differentially expressed in cancerous breast cells and their methods of use
11/03/2004	EP1472348A2 Light activated gene transduction using ultraviolet light for cell targeted gene delivery
11/03/2004	EP1472290A2 Cyclodextrin grafted biocompatible amphiphilic polymer and methods of preparation and use thereof
11/03/2004	EP1472288A2 Viral cd30 polypeptide
11/03/2004	EP1472269A1 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/03/2004	EP1472267A2 Rna interference mediated inhibition of protein tyrosine phosphatase type iva (prl3) gene expression using short interfering nucleic acid (sina)
11/03/2004	EP1471944A2 Pharmaceutical composition which improves in vivo gene transfer
11/03/2004	EP1471933A1 Albumin-fused anti-angiogenesis peptides
11/03/2004	EP1471928A1 Hiv inhibiting proteins
11/03/2004	EP1471926A2 Compositions and methods for the therapeutic use of an atonal-associated sequence
11/03/2004	EP1471922A2 METHODS AND MATERIALS FOR MODULATING TASK−3
11/03/2004	EP1471819A2 Composition and imaging methods for pharmacokinetic and pharmacodynamic evaluation of therapeutic delivery system
11/03/2004	EP1471818A2 Methods and compositions for treating hematological disorders using 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 or 13249 molecules
11/03/2004	EP0789708B1 Multifunctional molecular complexes for gene transfer to cells
11/03/2004	CN1543504A 疫苗 Vaccine
11/03/2004	CN1543476A Methods and compounds for the targeting of protein to exosomes
11/03/2004	CN1542132A Highly expressed recombinant virus containing human constant region all-antibody gene and its use for treating tumor
11/03/2004	CN1541714A Gene transfer-mediated angiogenesis therapy
11/03/2004	CN1541713A Cross-breed vaccine carrier and its application
11/03/2004	CN1541709A Polyepitope and composite polyepitope DNA vaccine of HIV
11/03/2004	CN1174099C Nucleic acid vaccines encoding G protein of respiratory syncytial virus
11/03/2004	CN1173745C Use of chemically modified methioninase in anti-methionine and anti-homocysteine chemotherapy
11/03/2004	CN1173744C Stable gene preparations
11/03/2004	CN1173738C Utilization of interferon alpha 5 in the preparation of drugs for viral hepatopathies
11/02/2004	US6812326 Tumor necrosis factor receptor-associated factor (traf) protein-interacting hereditary multiple extoses (trex) for use in the diagnosis and treatment of cancer and autoimmune disorders; antitummor agents
11/02/2004	US6812220 Pharmaceutical compositions and methods relating to fucans
11/02/2004	US6812218 Transferring nucleic acids to cells
11/02/2004	US6812206 Contacting body fluid from mammal with antibody which binds to human aspartyl (asparaginyl) beta-hydroxylase (haah) polypeptide under conditions sufficient to form antigen-antibody complex and detecting complex
11/02/2004	US6812027 Therapy for brain disorders
11/02/2004	US6811975 Phosphorothioate oligonucleotides having modified internucleoside linkages
11/02/2004	US6811774 Defective recombinant adenoviruses expressing cytokines for antitumor treatment
11/02/2004	US6811773 Human monocyte colony inhibitory factor (M-CIF) polypeptides
10/2004
10/28/2004	WO2004092731A1 Element having bioactive substance fixed thereto
10/28/2004	WO2004092397A2 Tmprss2 regulatory sequences and uses thereof
10/28/2004	WO2004092395A2 Modulators of telomere stability
10/28/2004	WO2004092388A1 Vector
10/28/2004	WO2004092352A2 Disruption of the reg pathway
10/28/2004	WO2004092343A2 Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
10/28/2004	WO2004092340A2 Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
10/28/2004	WO2004092216A1 Carcinoembryonic antigen (cea) lacking a signal peptide, nucleic acid encoding it and fusion of cea with a t cell epitope and their use for the treatment and/or prophylaxis of cancer
10/28/2004	WO2004091609A2 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
10/28/2004	WO2004091500A2 Delivery of immune response modifier compounds
10/28/2004	WO2004091479A2 Gene amplification and overexpression in cancer
10/28/2004	WO2004076626A3 Methods of gene therapy for treating disorders of the ear by administering a vector encoding an atonal-associated factor
10/28/2004	WO2004071418A3 Compounds for the treatment of systemic lupus erythematosus
10/28/2004	WO2004061456A3 Uses of hmgb, hmgn, hmga proteins
10/28/2004	WO2004046339A3 Caged sensors, regulators and compounds and uses thereof
10/28/2004	WO2004045496A3 Compositions and devices comprising or encoding the run x2 protein and method of use
10/28/2004	WO2004043386A3 Molecules preferentially associated with effector t cells and methods of their use
10/28/2004	WO2004032867A3 Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use
10/28/2004	WO2004018709A3 Single nucleotide polymorphisms predicting adverse drug reactions and drug efficacy in cardiovascular disease
10/28/2004	WO2004013313A3 Antisense nucleic acids
10/28/2004	WO2004003157A3 Gene regulation in transgenic animals using a transposon-based vector
10/28/2004	WO2003099991A3 Glp-1 gene delivery for the treatment of type 2 diabetes
10/28/2004	WO2003095613A3 Nucleic acids, polypeptides, and methods for modulating apoptosis
10/28/2004	WO2003089573A3 Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof
10/28/2004	WO2003066825A3 Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
10/28/2004	WO2003057827A3 Insulin-responsive dna binding protein-1 and methods to regulate insulin-responsive genes
10/28/2004	WO2003022882A3 Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle
10/28/2004	WO2003020954A3 205p1b5 in treatment and detection of cancer
10/28/2004	WO2001081540A3 Growth factor which acts through erb b-4 rtk
10/28/2004	US20040215251 Genetic modification of targeted regions of the cardiac conduction system
10/28/2004	US20040215007 Comprises nucleotide sequences coding polypeptide for use in identifying modulators for treatment of cell proliferative, nervous system and inflammatory diseases
10/28/2004	US20040215006 Oligonucleotide sequences for treatment and prevention of cell proliferative and skin disorders; gene expression inhibition; antisense agents
10/28/2004	US20040214999 Novel compounds for chemiluminescense procedures
10/28/2004	US20040214994 Genetically engineered immunoglobulin specific for hepatitis helicase for use in prevention and treatment of infection; immunotherapy
10/28/2004	US20040214990 Transmembrane protein differentially expressed in cancer
10/28/2004	US20040214792 Methods of treating inflammation
10/28/2004	US20040214786 Heterostructure component
10/28/2004	US20040214783 Compositions and methods for treatment of neoplastic disease
10/28/2004	US20040214771 Cleaved serum response factor in cardiac diagnosis and therapy
10/28/2004	US20040214765 Methods and means for inhibition of CDK4 activity
10/28/2004	US20040214761 induction of apoptosis in tumor cells by administering monoclonal antibodies
10/28/2004	US20040214759 Compositions and methods of use for a fibroblast growth factor
10/28/2004	US20040214332 Stable, multipotent transgenic nervous system progenitor tissue for treatment and prevention of neurodegenerative disorders
10/28/2004	US20040214329 Circular nucleic acid vectors, and methods for making and using the same
10/28/2004	US20040214328 Multifunctional molecular complexes for gene transfer to cells
10/28/2004	US20040214303 Complex
10/28/2004	US20040214286 Comprises nucleotide sequences coding cell growth factors for use in developing modulators for treatment of cell proliferative, arthritic, skin and vision defects; immunotherapy
10/28/2004	US20040214277 Methods and compositions for polypeptide engineering
10/28/2004	US20040214275 Von willebrand factor (vmf)-cleaving enzyme
10/28/2004	US20040214270 Isocitrate dehydrogenase, gene thereof, and use of the same in the treatment of obesity, hyperlipidemia, and fattly liver in lipid biosynthesis
10/28/2004	US20040214264 Comprises nucleotide sequences coding dimethylarginine dimethylaminohydrolase-1 protein (DDAH1) for use in identifying modulators for treatment of diabetes and cardiovascular disorders
10/28/2004	US20040214214 Nucleotide sequences coding obesity polypeptide for use in the diagnosis and treatment of viral, cell proliferative weight control and eating disorders

1 ... 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 ... 870